Potential conflict of interest: Dr. Zoulim consults for and received grants from Gilead, Bristol-Myers Squibb, and Roche. Dr. Lascoux-Combe consults for and received grants from Janssen. She also consults for Gilead and received grants from Roche.
High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B–infected patients
Version of Record online: 25 JUN 2013
Copyright © 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 3, pages 912–922, September 2013
How to Cite
Lacombe, K., Boyd, A., Lavocat, F., Pichoud, C., Gozlan, J., Miailhes, P., Lascoux-Combe, C., Vernet, G., Girard, P.-M. and Zoulim, F. (2013), High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B–infected patients. Hepatology, 58: 912–922. doi: 10.1002/hep.26374
This study was supported by grants from the Agence Nationale de Recherche sur le Sida et les Hépatites (ANRS), SIDACTION, and the European Community (HepBvar project contract QLRT2001-00977 and VIRGIL network contract LSHMCT- 2004-503359). Gilead Sciences, Inc., provided an unrestricted grant for the French HIV-HBV cohort and was not involved in any part of the data collection, analysis, or manuscript writing. A. B. was awarded a postdoctoral fellowship from the ANRS.
- Issue online: 29 AUG 2013
- Version of Record online: 25 JUN 2013
- Accepted manuscript online: 6 MAR 2013 05:22PM EST
- Manuscript Accepted: 28 FEB 2013
- Manuscript Received: 18 OCT 2012
Additional Supporting Information may be found in the online version of this article.
Supporting Table 1. Univariate analysis on risk-factors for HBV S-gene mutations at inclusion and during follow-up (L-nucleoside-associated pol-gene/antiviral-associated S-gene)
Supporting Table 2. Full description of HBV mutations at inclusion and during follow-up
Supporting Table 3. Clinical and virological description of patients with liver biopsies
Supporting Figure 1. Handling missing HBV mutation data
Supporting Figure 2. Clinical description of liver enzymes and HBV-DNA viral load during follow-up among several patients with incident S-gene mutations
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.